- Home
- IONS vs VVV Comparison
IONS vs VVV Comparison
Compare IONS & VVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- VVV
- Stock Information
- Founded
- IONS 1989
- VVV 1866
- Country
- IONS United States
- VVV United States
- Employees
- IONS N/A
- VVV N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- VVV Major Chemicals
- Sector
- IONS Health Care
- VVV Industrials
- Exchange
- IONS Nasdaq
- VVV Nasdaq
- Market Cap
- IONS 6.0B
- VVV 5.5B
- IPO Year
- IONS 1991
- VVV 2016
- Fundamental
- Price
- IONS $37.32
- VVV $38.12
- Analyst Decision
- IONS Buy
- VVV Buy
- Analyst Count
- IONS 18
- VVV 8
- Target Price
- IONS $62.00
- VVV $46.25
- AVG Volume (30 Days)
- IONS 1.5M
- VVV 1.8M
- Earning Date
- IONS 11-06-2024
- VVV 02-04-2025
- Dividend Yield
- IONS N/A
- VVV N/A
- EPS Growth
- IONS N/A
- VVV N/A
- EPS
- IONS N/A
- VVV 1.61
- Revenue
- IONS $803,067,000.00
- VVV $1,619,000,000.00
- Revenue This Year
- IONS N/A
- VVV $6.55
- Revenue Next Year
- IONS $19.61
- VVV $12.35
- P/E Ratio
- IONS N/A
- VVV $23.51
- Revenue Growth
- IONS 30.57
- VVV 12.16
- 52 Week Low
- IONS $33.33
- VVV $33.86
- 52 Week High
- IONS $54.44
- VVV $48.27
- Technical
- Relative Strength Index (RSI)
- IONS 52.98
- VVV 40.05
- Support Level
- IONS $36.39
- VVV $37.69
- Resistance Level
- IONS $38.90
- VVV $40.13
- Average True Range (ATR)
- IONS 1.33
- VVV 0.86
- MACD
- IONS 0.23
- VVV -0.05
- Stochastic Oscillator
- IONS 51.63
- VVV 18.12
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About VVV Valvoline Inc.
Valvoline Inc produces, markets, and sells automotive maintenance products, particularly lubricants, to retail outlets installers, and customers. The company offers various products such as engine oil, heavy-duty engine oil, motorcycle oil, grease and brake fluid, and others. Geographically, the majority of the revenue is generated from the United States of America.